 |
 Video: What is a Stock Split?
|
|
|
| Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. According to our Exelixis stock split history records, Exelixis has had 0 splits. | |
|
Exelixis (EXEL) has 0 splits in our Exelixis stock split history database.
Looking at the Exelixis stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Exelixis shares, starting with a $10,000 purchase of EXEL, presented on a split-history-adjusted basis factoring in the complete Exelixis stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$3.58 |
|
| End price/share: |
$22.49 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
528.21% |
|
| Average Annual Total Return: |
20.18% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$62,820.77 |
|
| Years: |
10.00 |
|
|
|
|
|
